[go: up one dir, main page]

PL3131549T3 - Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu - Google Patents

Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu

Info

Publication number
PL3131549T3
PL3131549T3 PL15739213T PL15739213T PL3131549T3 PL 3131549 T3 PL3131549 T3 PL 3131549T3 PL 15739213 T PL15739213 T PL 15739213T PL 15739213 T PL15739213 T PL 15739213T PL 3131549 T3 PL3131549 T3 PL 3131549T3
Authority
PL
Poland
Prior art keywords
befiradol
movement disorders
treating movement
treating
disorders
Prior art date
Application number
PL15739213T
Other languages
English (en)
Inventor
Bruno Paillard
Laurence DEL FRARI
Valérie BRUNNER
Adrian NEWMAN TANCREDI
Mark Varney
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of PL3131549T3 publication Critical patent/PL3131549T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL15739213T 2014-07-09 2015-07-09 Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu PL3131549T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022462P 2014-07-09 2014-07-09
PCT/EP2015/065763 WO2016005527A1 (en) 2014-07-09 2015-07-09 A method for treating movement disorders with befiradol
EP15739213.5A EP3131549B1 (en) 2014-07-09 2015-07-09 A method for treating movement disorders with befiradol

Publications (1)

Publication Number Publication Date
PL3131549T3 true PL3131549T3 (pl) 2018-09-28

Family

ID=53682662

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15739213T PL3131549T3 (pl) 2014-07-09 2015-07-09 Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu

Country Status (16)

Country Link
US (3) US10548885B2 (pl)
EP (1) EP3131549B1 (pl)
JP (2) JP6636458B2 (pl)
KR (1) KR102533428B1 (pl)
CN (1) CN106456622B (pl)
AU (1) AU2015286675B2 (pl)
CA (1) CA2946829C (pl)
DK (1) DK3131549T3 (pl)
ES (1) ES2668379T3 (pl)
HU (1) HUE037945T2 (pl)
MX (1) MX374938B (pl)
PL (1) PL3131549T3 (pl)
PT (1) PT3131549T (pl)
RU (1) RU2702101C2 (pl)
WO (1) WO2016005527A1 (pl)
ZA (1) ZA201607419B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3131549T (pt) * 2014-07-09 2018-07-04 Pf Medicament Método para tratar distúrbios do movimento com befiradol
WO2018057576A1 (en) 2016-09-22 2018-03-29 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
US11191758B2 (en) 2017-07-20 2021-12-07 Neurolixis Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
US6060345A (en) * 1997-04-21 2000-05-09 Advanced Micro Devices, Inc. Method of making NMOS and PMOS devices with reduced masking steps
FR2820743B1 (fr) 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
DE602005013244D1 (de) 2004-08-12 2009-04-23 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontroll
US7040843B1 (en) 2005-03-17 2006-05-09 Great Lakes Custom Tool Mfg., Inc. Flooring hollow back relief cutting tool and method
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2011008546A2 (en) 2009-06-29 2011-01-20 Capricorn Pharma, Inc. Solid and semi-solid dosage forms and systems and methods for forming and packaging thereof
JP5699339B2 (ja) 2010-02-12 2015-04-08 日産化学工業株式会社 徐放性製剤
BR112012024019B1 (pt) * 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
WO2012030314A1 (en) 2010-09-01 2012-03-08 Mithridion, Inc. Compositions comprising 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine, and methods of administering same
SI2627328T1 (sl) * 2010-10-15 2017-01-31 Contera Pharma Aps Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
CA2839350A1 (en) * 2011-07-05 2013-01-10 Contera Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
DK2838825T3 (en) 2012-04-18 2018-11-26 Jesco Holding Aps Winding apparatus for winding a web material into a roller
RU2670272C2 (ru) * 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
PT3131549T (pt) * 2014-07-09 2018-07-04 Pf Medicament Método para tratar distúrbios do movimento com befiradol
WO2025035048A1 (en) 2023-08-09 2025-02-13 Via Separations, Inc. Filtration apparatus comprising polymer modified graphene oxide membranes

Also Published As

Publication number Publication date
CN106456622A (zh) 2017-02-22
CA2946829C (en) 2018-05-22
US10548885B2 (en) 2020-02-04
US20210338646A1 (en) 2021-11-04
JP2017524651A (ja) 2017-08-31
ES2668379T3 (es) 2018-05-17
DK3131549T3 (en) 2018-05-28
HUE037945T2 (hu) 2018-09-28
RU2016143875A (ru) 2018-08-10
AU2015286675A1 (en) 2016-11-24
US11090298B2 (en) 2021-08-17
BR112016026648A2 (pt) 2017-08-15
RU2702101C2 (ru) 2019-10-04
PT3131549T (pt) 2018-07-04
MX374938B (es) 2025-03-06
WO2016005527A1 (en) 2016-01-14
CA2946829A1 (en) 2016-01-14
JP6636458B2 (ja) 2020-01-29
MX2016014740A (es) 2017-03-06
US20200138800A1 (en) 2020-05-07
US12472169B2 (en) 2025-11-18
JP2018138568A (ja) 2018-09-06
JP6824924B2 (ja) 2021-02-03
US20170239231A1 (en) 2017-08-24
EP3131549A1 (en) 2017-02-22
KR20170029407A (ko) 2017-03-15
ZA201607419B (en) 2023-12-20
AU2015286675B2 (en) 2017-08-24
CN106456622B (zh) 2020-05-19
EP3131549B1 (en) 2018-03-28
RU2016143875A3 (pl) 2019-02-01
BR112016026648A8 (pt) 2021-07-20
KR102533428B1 (ko) 2023-05-16

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL249981A0 (en) Method
PL3167096T3 (pl) Dwuetapowy sposób nanoszenia
DK3851537T5 (da) Behandling af hyperbilirubinæmi
IL256912B1 (en) Methods of treating developmental disorders with gaboxadol
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
DK3231444T3 (da) Ny behandling
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3132009T3 (da) Fremgangsmåde
BR112016022976A2 (pt) Métodos para o tratamento de hcv
PL3393468T3 (pl) Metody leczenia niedoboru odporności
PL3204150T3 (pl) Sposób wytwarzania nanocząstek
DK3283210T3 (da) Fremgangsmåde
IL257764B (en) Methods for treatment of diseases
IL251769A0 (en) Methods for treating eye conditions
FI20145633A7 (fi) Menetelmä biolietteen käsittelemiseksi
IL252086A0 (en) Novel methods
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi
HRP20181805T1 (hr) Postupak za proizvodnju poligvanidina
FR3024647B1 (fr) Transat de puericulture
PL3131549T3 (pl) Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
DK3200783T3 (da) Behandling af erytromelalgi
IL252707A0 (en) Compositions and methods for treating diseases and conditions
DK3285588T3 (da) Fremgangsmåde
PL3237368T3 (pl) Sposób oczyszczania laktylanu